NZ298144A - Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom - Google Patents

Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom

Info

Publication number
NZ298144A
NZ298144A NZ298144A NZ29814495A NZ298144A NZ 298144 A NZ298144 A NZ 298144A NZ 298144 A NZ298144 A NZ 298144A NZ 29814495 A NZ29814495 A NZ 29814495A NZ 298144 A NZ298144 A NZ 298144A
Authority
NZ
New Zealand
Prior art keywords
group
mono
atom
tetrahydro
substituted
Prior art date
Application number
NZ298144A
Other languages
English (en)
Inventor
Makoto Takeuchi
Ryo Naito
Masahiko Hayakawa
Yoshinori Okamoto
Yasuhiro Yonetoku
Ken Ikeda
Isomura Yasuo
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ298144(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NZ298144A publication Critical patent/NZ298144A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K19/00—Liquid crystal materials
    • C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
    • C09K19/06—Non-steroidal liquid crystal compounds
    • C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
    • C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
    • C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Tea And Coffee (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ298144A 1994-12-28 1995-12-27 Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom NZ298144A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP32704594 1994-12-28
PCT/JP1995/002713 WO1996020194A1 (en) 1994-12-28 1995-12-27 Novel quinuclidine derivatives and medicinal composition thereof

Publications (1)

Publication Number Publication Date
NZ298144A true NZ298144A (en) 1998-04-27

Family

ID=18194699

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ298144A NZ298144A (en) 1994-12-28 1995-12-27 Quinuclidine derivatives having muscarinic receptor antagonistic activity and medicaments therefrom

Country Status (24)

Country Link
US (2) US6017927A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0801067B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3014457B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100386487B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1045601C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE233761T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU695616B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2208839C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE69529844T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0801067T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2193208T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI115631B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR04C0032I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU223778B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU91133I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9704880A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300141I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (4) NO2005012I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ298144A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL182344B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT801067E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2143432C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW305842B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996020194A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128028A2 (en) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
FR2772378B1 (fr) * 1997-12-12 2000-02-04 Synthelabo Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) * 2000-05-02 2001-11-16 Dainippon Ink & Chem Inc 液晶組成物
EA005520B1 (ru) 2000-06-27 2005-04-28 Лабораториос С.А.Л.В.А.Т.,С.А. Карбаматы, полученные из арилалкиламинов
BR0116450A (pt) * 2000-12-22 2003-09-30 Almirall Prodesfarma Ag Composto, processos para a preparação de um carbamato, e para produzir um sal, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, produto de combinação
CA2433128C (en) 2000-12-28 2010-05-25 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
DK1405638T3 (da) * 2001-07-10 2011-04-18 Astellas Pharma Inc Farmaceutisk sammensætning omfattende quinuclidin-3'-yl-1-phenyl-1,2,3,4,-tetrahydroisoquinolin-2-carboxylat til behandling af interstitiel cystitis og/eller abakteriel prostatitis
EA006505B1 (ru) 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
JP4466370B2 (ja) * 2002-06-07 2010-05-26 アステラス製薬株式会社 過活動膀胱治療剤
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7399779B2 (en) 2002-07-08 2008-07-15 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
AU2002368152A1 (en) 2002-07-31 2004-02-25 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0)hexane derivatives useful as muscarinic receptor antagonists
WO2004014363A1 (en) 2002-08-09 2004-02-19 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonist
US7288562B2 (en) 2002-08-23 2007-10-30 Ranbaxy Laboratories Limited Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
JP2006511494A (ja) * 2002-10-29 2006-04-06 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗ムスカリン剤としてのキヌクリジニウム誘導体
AU2002353286A1 (en) 2002-12-10 2004-06-30 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
ATE368456T1 (de) * 2002-12-20 2007-08-15 Dynogen Pharmaceuticals Inc Behandlung nicht-schmerzhafter blasenstörungen mit modulatoren von alpha-2-delta- calciumkanaluntereinheiten
US7501443B2 (en) 2002-12-23 2009-03-10 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
EP1583741A1 (en) 2002-12-23 2005-10-12 Ranbaxy Laboratories, Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE345120T1 (de) * 2003-03-21 2006-12-15 Dynogen Pharmaceuticals Inc Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
AU2003214520A1 (en) 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615887A1 (en) 2003-04-10 2006-01-18 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
NZ542952A (en) 2003-04-11 2008-11-28 Ranbaxy Lab Ltd Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
JPWO2005075474A1 (ja) * 2004-02-09 2007-10-11 アステラス製薬株式会社 コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) * 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
JPWO2005087231A1 (ja) * 2004-03-16 2008-01-24 アステラス製薬株式会社 ソリフェナシン含有組成物
EP1726304A4 (en) * 2004-03-16 2010-04-28 Astellas Pharma Inc COMPOSITION CONTAINING SOLIFENACIN
US8039482B2 (en) * 2004-03-25 2011-10-18 Astellas Pharma Inc. Composition of solifenacin or salt thereof for use in solid formulation
CN101601673B (zh) * 2004-03-25 2012-07-18 安斯泰来制药株式会社 用于固体制剂的索非那新或其盐的组合物
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090105221A1 (en) * 2004-09-29 2009-04-23 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
DE602005019094D1 (de) * 2004-12-22 2010-03-11 Memory Pharmaceutical Corp Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns
WO2006070735A1 (ja) 2004-12-27 2006-07-06 Astellas Pharma Inc. ソリフェナシンまたはその塩の安定な粒子状医薬組成物
BRPI0519270A2 (pt) * 2004-12-27 2009-01-06 Astellas Pharma Inc composiÇço farmacÊutica particulada estÁvel de solifenacina ou um sal
EP1852117A4 (en) * 2005-02-25 2010-10-27 Astellas Pharma Inc PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
JP3701964B1 (ja) * 2005-03-08 2005-10-05 アステラス製薬株式会社 キヌクリジン誘導体の新規な塩
WO2007007281A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
CA2626612A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
EP1879867A2 (en) * 2005-12-21 2008-01-23 Teva Pharmaceutical Industries Ltd Intermediates for preparing solifenacin
CZ300699B6 (cs) * 2006-06-21 2009-07-22 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008011462A2 (en) * 2006-07-19 2008-01-24 Dr. Reddy's Laboratories Ltd. Process for preparing solifenacin and its salts
ES2298049B1 (es) * 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (en) * 2006-07-24 2009-04-08 Teva Pharmaceutical Industries Ltd. Processes for preparing polymorphic forms of solifenacin succinate
EP1922308A2 (en) * 2006-08-03 2008-05-21 Teva Pharmaceutical Industries Ltd. Processes for optical resolution of 1-phenyl-1,2,3,4-tetrahydroisoquinoline
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
US20100029944A1 (en) * 2006-11-22 2010-02-04 Corporacion Medichem, S.L. Process for the Synthesis of Solifenacin
CZ300692B6 (cs) * 2006-12-22 2009-07-15 Zentiva, A. S. Zpusob prípravy solifenacinu
WO2008120080A2 (en) * 2007-03-30 2008-10-09 Medichem, S.A. An improved process for the synthesis of solifenacin
WO2009011844A1 (en) * 2007-07-13 2009-01-22 Teva Pharmaceutical Industries Ltd. Processes for solifenacin preparation
WO2009013846A1 (ja) 2007-07-20 2009-01-29 Astellas Pharma Inc. 前立腺肥大に伴う下部尿路症状の改善用医薬組成物
EP2018850A1 (en) * 2007-07-24 2009-01-28 Ratiopharm GmbH Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
WO2009057685A1 (ja) * 2007-11-02 2009-05-07 Astellas Pharma Inc. 過活動膀胱治療用医薬組成物
US8476297B2 (en) 2007-12-04 2013-07-02 Amgen Inc. TRP-M8 receptor ligands and their use in treatments
EP2484681A1 (en) 2007-12-04 2012-08-08 Cadila Healthcare Limited Chemically and chirally pure gentisate salt of solifenacin
ITMI20080195A1 (it) 2008-02-08 2009-08-09 Dipharma Francis Srl Procedimento per la preparazione di solifenacin
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US8404701B2 (en) 2008-03-27 2013-03-26 Chase Pharmaceuticals Corporation Use and composition for treating dementia
PL385264A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
PL385265A1 (pl) 2008-05-23 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
SI3067353T1 (en) 2008-07-29 2018-03-30 Krka, D.D., Novo Mesto Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
BRPI1007484B1 (pt) * 2009-02-04 2019-04-16 Astellas Pharma Inc. Composição farmacêutica formulada para administração oral compreendendo uma camada compreendendo uma porção de liberação modificada e uma camada compreendendo uma porção de liberação imediata
US8283470B2 (en) 2009-03-09 2012-10-09 Megafine Pharma(P) Ltd. Method for the preparation of solifenacin and intermediate thereof
WO2010113840A1 (ja) 2009-03-30 2010-10-07 アステラス製薬株式会社 ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en) 2009-09-25 2011-04-28 Cadila Healthcare Limited Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl) 2010-01-18 2020-01-31 Zakl Farmaceutyczne Polpharma Spolka Akcyjna Sposób wytwarzania bursztynianu solifenacyny
EP2554184B1 (en) 2010-03-31 2016-10-26 ONO Pharmaceutical Co., Ltd. Preventive and/or remedy for hand and foot syndrome
EP2563123B1 (en) 2010-04-30 2018-04-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
MX2012013328A (es) 2010-05-19 2013-02-01 Astellas Pharma Inc Composicion farmaceutica que contiene solifenacina.
WO2012001481A1 (en) 2010-06-28 2012-01-05 Aurobindo Pharma Limited Novel process for the preparation of solifenacin succinate
CA2804107A1 (en) 2010-07-05 2012-01-12 Crystal Pharma S.A.U. Solifenacin salts
EP2638039A1 (de) 2010-11-11 2013-09-18 Hexal AG Kristallines solifenacin-succinat
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
AU2012253667B2 (en) 2011-05-10 2017-06-01 Theravida, Inc. Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder
JP2014520126A (ja) 2011-06-22 2014-08-21 イソケム ソリフェナシンおよびその塩の製造方法
KR101365849B1 (ko) 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
WO2014005601A1 (en) 2012-07-02 2014-01-09 Pharmathen S.A. A process for the preparation of solifenacin or a salt thereof
JPWO2014034860A1 (ja) 2012-08-31 2016-08-08 アステラス製薬株式会社 経口投与用医薬組成物
IN2015DN01706A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-09-05 2015-05-22 Chase Pharmaceuticals Corp
CN103787969B (zh) 2012-10-30 2016-07-06 上海京新生物医药有限公司 一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
BR112015012746A2 (pt) * 2012-12-06 2017-07-11 Chiesi Farm Spa compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
EP2778167A1 (en) 2013-03-11 2014-09-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
CA2921621C (en) * 2013-07-13 2018-08-28 Beijing Fswelcome Technology Development Co., Ltd Quinine compounds, and optical isomers, preparation method and medical use thereof
WO2015171753A1 (en) 2014-05-06 2015-11-12 Visco Anthony G Methods of treating or preventing preterm labor
CN104592221A (zh) * 2015-01-26 2015-05-06 中山奕安泰医药科技有限公司 一种合成索非那新的工艺
KR20160146428A (ko) 2015-06-12 2016-12-21 한미정밀화학주식회사 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko) 2017-05-15 2020-08-26 주식회사 서울제약 솔리페나신을 유효성분으로 하는 구강붕해필름
TW201927783A (zh) * 2017-12-12 2019-07-16 美商阿爾庫達醫療公司 顆粒體蛋白前體調節劑及其使用方法
BR112020022662A2 (pt) 2018-05-08 2021-02-09 Nippon Shinyaku Co., Ltd. compostos de azabenzimidazol e farmacêuticos
AU2020290485A1 (en) * 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CN113200979A (zh) * 2021-04-13 2021-08-03 上海予君生物科技发展有限公司 一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247266B1 (en) * 1986-01-07 1993-03-10 Beecham Group Plc Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
IT1231238B (it) * 1987-09-21 1991-11-26 Angeli Inst Spa Derivati ammidinici
IT1228293B (it) * 1989-02-06 1991-06-07 Angeli Inst Spa Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) * 1990-10-23 1990-12-05 Barlow Richard B Pharmaceutical compositions
GB9202443D0 (en) * 1992-02-05 1992-03-18 Fujisawa Pharmaceutical Co A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) * 1993-06-18 1995-01-10 Sony Corp 信号伝送ケーブル
AU7545894A (en) * 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
JPH07258250A (ja) * 1994-03-25 1995-10-09 Yamanouchi Pharmaceut Co Ltd エステル誘導体
ATE339121T1 (de) * 2002-11-27 2006-10-15 Selmac S R L Vorrichtung zum positionieren und spannen geformter teile und damit ausgerüstete maschine

Also Published As

Publication number Publication date
AU4355396A (en) 1996-07-19
PT801067E (pt) 2003-07-31
LU91133I9 (en) 2018-08-01
LU91133I2 (fr) 2005-03-29
WO1996020194A1 (en) 1996-07-04
DK0801067T3 (da) 2003-06-30
DE69529844T2 (de) 2004-03-04
NO2005012I1 (no) 2005-06-06
HUT77006A (hu) 1998-03-02
EP0801067A1 (en) 1997-10-15
NO2017055I1 (no) 2017-11-06
FR04C0032I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2005-02-11
EP0801067B1 (en) 2003-03-05
DE122004000048I2 (de) 2006-02-02
FR04C0032I2 (fr) 2005-10-21
PL182344B1 (pl) 2001-12-31
FI972775A0 (fi) 1997-06-27
ATE233761T1 (de) 2003-03-15
NO2005016I2 (no) 2008-02-11
DE69529844D1 (de) 2003-04-10
TW305842B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-05-21
US6174896B1 (en) 2001-01-16
NO2005016I1 (no) 2005-08-29
CN1171109A (zh) 1998-01-21
NO973027L (no) 1997-08-28
ES2193208T3 (es) 2003-11-01
NO318026B1 (no) 2005-01-24
NO973027D0 (no) 1997-06-27
PL321019A1 (en) 1997-11-24
AU695616B2 (en) 1998-08-20
RU2143432C1 (ru) 1999-12-27
CA2208839C (en) 2006-01-31
EP0801067A4 (en) 1998-03-11
CA2208839A1 (en) 1996-07-04
NL300141I2 (nl) 2004-04-01
NL300141I1 (nl) 2004-04-01
US6017927A (en) 2000-01-25
FI972775A7 (fi) 1997-08-22
HU223778B1 (hu) 2005-01-28
NO2017055I2 (no) 2017-11-06
CN1045601C (zh) 1999-10-13
FI115631B (fi) 2005-06-15
JP3014457B2 (ja) 2000-02-28
MX9704880A (es) 1997-10-31
KR987000303A (ko) 1998-03-30
DE122004000048I1 (de) 2005-04-21
JPH09508401A (ja) 1997-08-26
KR100386487B1 (ko) 2003-09-26

Similar Documents

Publication Publication Date Title
EP0801067B1 (en) Novel quinuclidine derivatives and medicinal composition thereof
WO1997047601A1 (fr) Composes heterocycliques fusionnes et leurs utilisations medicinales
US7078409B2 (en) Fused quinazoline derivatives useful as tyrosine kinase inhibitors
WO1995006635A1 (fr) Derive de carbamate et medicament le contenant
EP0915094B1 (en) Morphinane derivatives and medicinal use thereof
EP0747355A1 (en) Novel carbamate derivative and medicinal composition containing the same
JPS6043342B2 (ja) イソキノリニウム化合物
EP0453197B1 (en) Amine derivatives
US5968949A (en) Substituted hydroisoquinoline derivatives and their use as pharmaceuticals
KR100241662B1 (ko) 히드로이소퀴놀린 유도체
NO142838B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater.
JP2003267977A (ja) キヌクリジン誘導体
AU2006316706A1 (en) Isoquinoline and benzo[H]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine H3 receptor
KR19990077033A (ko) Cns 활성을 갖는 4,5-디히드로나프트[1,2-c]이속사졸 및그의 유도체
DK174564B1 (da) Benzazepinderivater, der er substitueret i 3-stillingen med en N-phenylalkyl-cycloalkyleniminogruppe, og lægemidler indeholdende sådanne forbindelser
DK161200B (da) 11-substituerede 5,11-dihydro-6h-pyridooe2,3-baaoe1,4aa-benzodiazepin-6-oner, fremgangsmaade til fremstilling heraf, laegemiddel indeholdende en saadan forbindelse samt anvendelse af en saadan forbindelse tilfremstilling af laegemidler
WO1999038864A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
JP2000109481A (ja) キヌクリジン誘導体含有医薬
EP0446921A2 (en) Optically active alkylene-dioxybenzene derivatives and their use in therapy
WO1993003011A1 (en) Urea derivative
NZ231634A (en) Tetrahydrothiopyrano- and pentahydrothiepino-(2,3,-b)indole derivatives and pharmaceutical compositions
KR100824506B1 (ko) 퀴나졸리논 유도체
US4198418A (en) Spiro[dibenz(b,f)oxepin-piperidine]s
IL97852A (en) 4-(3-(4-oxothiazolidinyl)) butynylamines, a process for their preparation and their use as medicaments
US4281130A (en) Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: ASTELLAS PHARMA INC., JP

Free format text: OLD OWNER(S): YAMANOUCHI PHARMACEUTICAL CO., LTD.

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired